Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin dose comparison for depression in adults with heart failure with reduced ejection fraction
IRCT20111206008307N41Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of empagliflozin in heart failure with reduced ejection fraction (HFrEF) and major depressive disorder (MDD) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoint: Hamilton grading scale at month 3. Started Nov 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20111206008307N41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20111206008307N41.